Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Abbreviations: ↑: increase; ↓: decrease; 1,25(OH)2D3: 1,25-dihydroxyvitamin D3; 4-HNE: 4-hydroxynonenal; ABL: alveolar bone loss; ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; Bax: Bcl-2-associated X protein; Bcl-2: B-cell lymphoma 2; BFR/BS: bone formation rate/bone surface; BMD: bone mineral density; BrdU: bromodeoxyuridine; BS/BV: bone surface/bone volume; BUN: blood urea nitrogen; BV/TV: bone volume/tissue volume; Ca: calcium; CAT: catalase; c-Fos: cellular Fos; Col-1: collagen type I: Conn.D: connectivity density: Ct.Th: cortical thickness; CTX: C-terminal telopeptide of type I collagen; D-gal: D-galactose; DCX: doublecortin; F/B ratio: Firmicutes/Bacteroidetes ratio; Foxp3: forkhead box P3; GFAP: glial fibrillary acidic protein; Glu: glucose; GSH: reduced glutathione; GSH-Px: glutathione peroxidase; Hyp: hydroxyproline; Iba1: ionized calcium-binding adaptor molecule 1; ICR: Institute of Cancer Research: I.p.: intraperitoneal; IL-1α: interleukin 1 alpha; IL-1β: interleukin 1 beta; IL-6: interleukin 6; IL-17: interleukin 17; Ki-67: marker of cell proliferation Ki-67; LC3II: microtubule-associated protein 1 light chain 3 II; LDH: lactate dehydrogenase; MAR: mineral apposition rate; MDA: malondialdehyde; Mg: magnesium; MMP3: matrix metalloproteinase 3; MMP13: matrix metalloproteinase 13; NF-κB: nuclear factor kappa B; NeuN: neuronal nuclei; OCN: osteocalcin; OPG: osteoprotegerin; OPN: osteopontin; p16: cyclin-dependent kinase inhibitor 2A; p21: cyclin-dependent kinase inhibitor 1A; p53: tumor protein p53; p62: sequestosome 1; p65: nuclear factor κB p65 subunit; p-IκBα: phosphorylated inhibitor of κB alpha; P1NP: procollagen type I N-terminal propeptide; Pi: inorganic phosphate; PI3K/Akt: phosphoinositide 3-kinase/protein kinase B; pRB: retinoblastoma protein; PTH: parathyroid hormone; RANK: receptor activator of nuclear factor κB; RANKL: receptor activator of nuclear factor κB ligand; ROR-γt: retinoic acid receptor-related orphan receptor gamma t; ROS: reactive oxygen species; Runx-2: runt-related transcription factor 2; SASP: senescence-associated secretory phenotype: S.c.: subcutaneous; SIRT1: sirtuin 1; SMI: structure model index; SOD: superoxide dismutase; STAT-3: signal transducer and activator of transcription 3: Tb.Ar: trabecular area: Tb.BV/TV: trabecular bone volume/tissue volume: Tb.N: trabecular number: Tb.Sp: trabecular separation: Tb.Th: trabecular thickness; TC: total cholesterol; TG: triglycerides; Th17: T helper 17 cells; TNF-α: tumor necrosis factor alpha; TRACP: tartrate-resistant acid phosphatase; TRAP: tartrate-resistant acid phosphatase; Treg: regulatory T cells; TRIM16: tripartite motif containing 16; ZO-1: zonula occludens 1; β-gal: beta-galactosidase; γ-H2A.X: phosphorylated histone H2A.X.

Source: Rat models. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Scoping review.

Scoping review

Maps the extent and characteristics of research on a topic.

Meta-analysis unclear · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

D-galactose-induced osteoporosis in rodents: Model development, skeletal characteristics, and optimal dosing regimens: A scoping review

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

D-galactose-induced osteoporosis in rodents: Model development, skeletal characteristics, and optimal dosing regimens: A scoping review

Scoping review · Biomolecules and Biomedicine · 2026

Original publication title

D-galactose-induced osteoporosis in rodents: Model development, skeletal characteristics, and optimal dosing regimens: A scoping review

Yuanzhong Wang; Li Lian Goh; Kok-Yong Chin

© 2026 Wang et al.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

D-galactose has been extensively utilized as a compound to accelerate aging and induce osteoporosis in rodent models. However, variations in dosage, administration routes, and experimental protocols have resulted in inconsistent findings. This scoping review aims to compile preclinical evidence on the use of D-galactose to induce bone loss, with a particular focus on identifying optimal dosing regimens and their specific impacts on skeletal indices. A systematic literature search was conducted in PubMed, Scopus, and Web of Science using predefined terms related to D-galactose-induced osteoporosis in rodents.

Eligible studies were selected based on inclusion criteria, concentrating on both in vivo and in vitro models. A total of 44 studies met these criteria, primarily involving rats and mice. D-galactose was administered via subcutaneous, intraperitoneal, or oral routes, with doses ranging from 10 to 10,000 mg/kg/day for durations spanning 20 days to 5 months. The most commonly employed regimen was 200 mg/kg/day for 8 weeks. D-galactose consistently induced osteoporotic changes, including reduced bone mineral density, compromised microarchitecture, decreased biomechanical strength, and alterations in bone turnover markers.

These skeletal changes were associated with oxidative stress, cellular senescence, and ferroptosis. Susceptibility to these effects was influenced by sex, species, and age, with male rodents generally exhibiting greater sensitivity. In conclusion, D-galactose serves as an effective model for age-related osteoporosis in rodents, primarily mediated by oxidative stress and accelerated cellular senescence. A regimen of 200 mg/kg/day administered subcutaneously or intraperitoneally for 8 weeks is commonly used to replicate osteoporotic phenotypes. Greater standardization of protocols is necessary to enhance reproducibility and translational relevance in future studies.

Authors’ abstract

D-galactose has been extensively utilized as a compound to accelerate aging and induce osteoporosis in rodent models. However, variations in dosage, administration routes, and experimental protocols have resulted in inconsistent findings. This scoping review aims to compile preclinical evidence on the use of D-galactose to induce bone loss, with a particular focus on identifying optimal dosing regimens and their specific impacts on skeletal indices. A systematic literature search was conducted in PubMed, Scopus, and Web of Science using predefined terms related to D-galactose-induced osteoporosis in rodents.

Eligible studies were selected based on inclusion criteria, concentrating on both in vivo and in vitro models. A total of 44 studies met these criteria, primarily involving rats and mice. D-galactose was administered via subcutaneous, intraperitoneal, or oral routes, with doses ranging from 10 to 10,000 mg/kg/day for durations spanning 20 days to 5 months. The most commonly employed regimen was 200 mg/kg/day for 8 weeks. D-galactose consistently induced osteoporotic changes, including reduced bone mineral density, compromised microarchitecture, decreased biomechanical strength, and alterations in bone turnover markers.

These skeletal changes were associated with oxidative stress, cellular senescence, and ferroptosis. Susceptibility to these effects was influenced by sex, species, and age, with male rodents generally exhibiting greater sensitivity. In conclusion, D-galactose serves as an effective model for age-related osteoporosis in rodents, primarily mediated by oxidative stress and accelerated cellular senescence. A regimen of 200 mg/kg/day administered subcutaneously or intraperitoneally for 8 weeks is commonly used to replicate osteoporotic phenotypes. Greater standardization of protocols is necessary to enhance reproducibility and translational relevance in future studies.

Publication and source details

Original title: D-galactose-induced osteoporosis in rodents: Model development, skeletal characteristics, and optimal dosing regimens: A scoping review

Yuanzhong Wang; Li Lian Goh; Kok-Yong Chin

Biomolecules and Biomedicine · 2026

* Correspondence to Kok-Yong Chin: chinky@ukm.edu.my© 2026 Wang et al.2026https://creativecommons.org/licenses/by/4.0/This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T23:42:23.810646+00:00

DOI: 10.17305/bb.2026.13914 · PMC13668005